What one boy’s ‘Lazarus-like’ recovery tells us about the future of bio drugs

hardingdsc compressor
Cameron Harding; Photo credit: Leigh Webber
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

Shortly after Cameron Harding’s one-month check-up, his mother, Alison, saw that her newborn seemed to stop moving. She’d unwrap him from a swaddle and his arms would flop to one side. He wouldn’t kick his legs or turn his head.

The diagnosis: spinal muscular atrophy.

Cameron’s case was severe enough he’d probably never even have a birthday.

But when he was seven weeks old, Cameron’s parents enrolled him in a clinical trial for an experimental drug. In videos shot two months later, he could move his head and reach for a toy. No child with his condition had ever made such a recovery before.

The drug Cameron received, Spinraza, was approved in the U.S. just before Christmas and may become the first blockbuster in a novel category of drugs called RNA therapeutics…

What drugs like Spinraza seek to do instead is use RNA to block, modify, or add to, the existing RNA messages in a cell.

“The dirty secret of RNA therapies is that most people are working on stuff where there is competition and there are other molecules,” [Rachel Meyers, previously a senior executive at Alnylam] says. “It’s those ones that don’t have a good alternative where you say, ‘Oh my gosh, we can really change the world, or someone’s life, with this.’

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post: How a Boy’s Lazarus-like Revival Points to a New Generation of Drug

For more background on the Genetic Literacy Project, read GLP on Wikipedia.

Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
a a b b a f ac a

Video: Death by COVID: The projected grim toll in historical context

The latest statistics, as of July 10, show COVID-19-related deaths in U.S. are just under 1,000 per day nationally, which is ...
mag insects image superjumbo v

Disaster interrupted: Which farming system better preserves insect populations: Organic or conventional?

A three-year run of fragmentary Armageddon-like studies had primed the journalism pumps and settled the media framing about the future ...
dead bee desolate city

Are we facing an ‘Insect Apocalypse’ caused by ‘intensive, industrial’ farming and agricultural chemicals? The media say yes; Science says ‘no’

The media call it the “Insect Apocalypse”. In the past three years, the phrase has become an accepted truth of ...
types of oak trees

Infographic: Power of evolution? How oak trees came to dominate North American forests

Over the course of some 56 million years, oaks, which all belong to the genus Quercus, evolved from a single undifferentiated ...
biotechnology worker x

Can GMOs rescue threatened plants and crops?

Some scientists and ecologists argue that humans are in the midst of an "extinction crisis" — the sixth wave of ...
food globe x

Are GMOs necessary to feed the world?

Experts estimate that agricultural production needs to roughly double in the coming decades. How can that be achieved? ...
eating gmo corn on the cob x

Are GMOs safe?

In 2015, 15 scientists and activists issued a statement, "No Scientific consensus on GMO safety," in the journal Environmental Sciences ...
Screen Shot at PM

Charles Benbrook: Agricultural economist and consultant for the organic industry and anti-biotechnology advocacy groups

Independent scientists rip Benbrook's co-authored commentary in New England Journal calling for reassessment of dangers of all GMO crops and herbicides ...
Screen Shot at PM

ETC Group: ‘Extreme’ biotechnology critic campaigns against synthetic biology and other forms of ‘extreme genetic engineering’

The ETC Group is an international environmental non-governmental organization (NGO) based in Canada whose stated purpose is to monitor "the impact of emerging technologies and ...
Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend